Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Share:
Related EW
7 Biggest Price Target Changes For Wednesday
Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge
Edwards 2017 Guidance Likely Hinges On Rivalry With Medtronic, Boston (Investor's Business Daily)

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

DateFirmActionFromTo
Dec 2016Cowen & Co.MaintainsOutperformOutperform
Nov 2016Northland SecuritiesUpgradesMarket PerformOutperform
Jul 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!